Author name: ASolia

Axxam Researchers Present at the 11th SBS Conference in Geneva, Switzerland At the 11th Society of Biomedical Screening (SBS) Conference, Geneva (Switzerland), Axxam scientists made podium presentations on the following topics: Electrogenic proteins: from cell based assay generation to HTS applications”, Sabrina Corazza Comprehensive Gene Expression Profiling of GPCRs and Ion Channels”, Paola Tarroni Axxam […]

Axxam Awarded FIT Grant for Novel Target Identification Axxam is pleased to announce the award of a grant from the Italian Ministero delle Attività; Produttive (MAP). The grant of €2.93 million will support a three year project in the field of novel target identification for pharmaceutical screening and recognizes the contribution of Axxam to Technological

Axxam installed a new technology platform for performing robotic high throughput screening (HTS) and ultra high-throughput screening (uHTS) of chemical libraries. Axxam implemented the most advanced instrumentation (CyBiTM-Cellight (CyBio AG) and FLIPRtetraTM (Molecular Devices Corporation Inc.) in a highly integrated and centralized structure, capable of performing screening campaigns which can generate over a million test

Dompé pha.r.ma and Axxam Announce Drug Discovery and Development Collaboration Dompé pha.r.ma s.p.a. and Axxam SpA announced a research collaboration for the discovery and development of novel drugs based on GPCR targets. Scientists from both companies will contribute to the drug discovery and development process for relevant disease targets. Steps in the process include target

Axxam Receives European Patent for Innovative Technology Photina® Axxam is pleased to announce the award of European Patent number EP1413584, entitled “Photoprotein with improved bioluminescence”, describing the company’s proprietary photoprotein known as Photina®. The invention provides a chimeric photoprotein with improved luminescent activity and its use as a calcium indicator in reporter gene systems and

Axxam Collaborates with CyBio AG Axxam and CyBio have signed a contract to cooperate in the development and marketing of new technologies for drug discovery using automated luminescence screening systems. Open PDF document

Axxam Awarded € 1.1 million grant Axxam Awarded Substantial Funding by the Regione Lombardia (Metadistretti) with € 1.1 million grant to support one of the company’s innovative projects in the field of Cell-based Screening Assays. Open PDF document

Axxam Awarded € 6.7 million grant Axxam Awarded Substantial Funding by the Italian Ministry of Research (MIUR) with € 6.7 million grant to support the company’s projects in Drug Discovery Technologies. Open PDF document

Axxam Researchers Present at the 10th SBS Conference At the 10th SBS Conference, Orlando (Florida), Axxam representatives presented oral communications on the following topics: “A comprehensive GPCR assay platform”, Lia Scarabottolo “An integrated platform for high throughput expression of human proteases”, Daniele Carettoni

Photina® Patent The European Patent Office released a communication under Rule 51(4) with the intention to grant Axxam’s application n° 02 023 452.2, entitled “Photoprotein with improved bioluminescence”, which covers the use of Photina® in all European Countries. For the same subject a PCT Application has been filed for the rest of the world and